# Xenon Inhalation for Treatment of Posttraumatic Stress Disorder

> **NCT03635827** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nobilis Therapeutics Inc.** · enrollment: 190 (estimated)

## Conditions studied

- Post Traumatic Stress Disorder

## Interventions

- **COMBINATION_PRODUCT:** NBTX-001 Xenon Inhaler
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT03635827
- **Lead sponsor:** Nobilis Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06
- **Primary completion:** 2021-06
- **Final completion:** 2021-07
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635827, "Xenon Inhalation for Treatment of Posttraumatic Stress Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03635827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*